The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis

Critical Care Medicine

Volumn 32, Issue 12, 2004, Pages 2485-2490

  Giacometti, Andrea ^a   Cirioni, Oscar ^a   Ghiselli, Roberto ^a   Bergnach, Cristina ^b   Orlando, Fiorenza ^c   D'Amato, Giuseppina ^a   Mocchegiani, Federico ^a   Silvestri, Carmela ^a   Del Prete, Maria Simona ^a   Skerlavaj, Barbara ^b   Saba, Vittorio ^a   Zanetti, Margherita ^b,d   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c INRCA   (Italy)

^d National Laboratory CIB   (Italy)

Author keywords

Antimicrobial peptide; BMAP 28; Cathelicidins; Septic shock; Staphylococcal sepsis

Indexed keywords

ANTIMICROBIAL PEPTIDE BMAP 28; CLARITHROMYCIN; CLINDAMYCIN; IMIPENEM; INTERLEUKIN 6; ISOTONIC SOLUTION; NITRIC OXIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL GROWTH; BLOOD CULTURE; CELL KILLING; COLONY FORMING UNIT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; FEVER; INFLAMMATION; LETHALITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; PROBABILITY; PROTEINS; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10644276256     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000148221.09704.22     Document Type: Article

References (46)

1. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
2. Edgeworth JD, Treacher DF, Eykyn SJ: A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999; 27:1421-1428
3. Wenzel RP, Pinsky MR, Ulevitch RJ, et al: Current understanding of sepsis. Clin Infect Dis 1996; 22:407-413
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care. Crit Care Med 2001; 29:1303-1310
5. Bone RC: Gram-positive organisms and sepsis. Arch Intern Med 1994; 154:26-34
6. Griffith DC, Harford L, Williams R, et al: In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against Gram-positive bacteria. Antimicrob Agents Chemother 2003; 47:43-47
7. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
8. Tenover FC: Implications of vancomycin resistant Staphylococcus aureus. J Hosp Infect 1999; 43(Suppl):S3-S7
9. Raad I, Alrahwan A, Rolston K: Staphylococcus epidermidis emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26:1182-1187
10. De Kimpe SJ, Kengatharan M, Thiemermann C, et al: The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A 1995; 92:10359-10363
11. Ahmed A, Kruse J, Haupt M, et al: Hemodynamic responses to Gram-positive versus Gram-negative sepsis in critically ill patients with or without circulatory shock. Crit Care Med 1991; 19:1520-1525
12. Heumann D, Barras C, Severin A, et al: Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62:2715-2721
13. Timmerman CP, Mattsson E, Martinez-Martinez L, et al: Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993; 61:4167-4172
14. Kengatharan M, De Kimpe SJ, Robson C, et al: Mechanism of Gram-positive shock: Identification of peptidoglycan and lipoteichoic acid mioeties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 1998; 188:305-315
15. Visvanathan K, Charles A, Bannan J, et al: Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 2001; 69:875-884
16. Kum WW, Laupland KB, Chow AW: Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 2000; 46:171-179
17. Llewelyn M, Cohen J: Superantigens: Microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2:56-162
18. Barton BE, Shortall J, Jackson JV: Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996; 64:714-718
19. Scott MG, Gold MR, Hancock REW: Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria. Infect Immun 1999; 67:6445-6453
20. Peschel A, Otto M, Jack RW, et al: Inactivation of the dit operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999; 274:8405-8410
21. Mattsson E, Van Dijk H, Verhoef J, et al: Supernatants from Staphylococcus epidermidis grown in the presence of different antibiotics induce differential release of tumor necrosis factors alpha from human monocytes. Infect Immun 1996; 64:4351-4355
22. Van Amersfoort ES, Van Berkel TJC, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microb Rev 2003; 16:379-414
23. Riedemann NC, Guo RF, Ward PA: Novel strategies for the treatment of sepsis. Nature Med 2003; 9:517-524
24. Hancock REW, Scott MG: The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 2000; 97:856-861
25. Giacometti A, Cirioni O, Ghiselli R, et al: Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats. Gut 2003; 52:874-878
26. Gough M, Hancock REW, Kelly NM: Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64:4922-4927
27. Zanetti M, Gennaro R, Skerlavaj B, et al: Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr Pharm Des 2002; 8:779-793
28. Hancock RE, Patrzykat A: Clinical development of cationic peptides: From natural to novel antibiotics. Curr Drug Targets Infect Disord 2002; 2:79-83
29. Zanetti M: Cathelicidins, multifunctional peptides of the innate immunity. J Leuk Biol 2004; 75:39-48
30. Zanetti M, Gennaro R, Romeo D: Cathelicidins: A novel protein family with common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374:1-5
31. Gennaro R, Zanetti M: Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 2000; 55:31-49
32. Lehrer RI, Ganz T: Cathelicidins: A family of endogenous antimicrobial peptides. Curr Opin Hematol 2002; 9:18-22
33. Devine DA, Hancock RE: Cationic peptides: Distribution and mechanisms of resistance. Curr Pharm Des 2002; 8:703-714
34. Giacometti A, Cirioni O, Del Prete MS, et al: In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. J Antimicrob Chemother 2003; 51:843-847
35. Skerlavaj B, Gennaro R, Bagella LL, et al: Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem 1996; 271:28375-28381
36. Benincasa M, Skerlavaj B, Gennaro R, et al: In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs. Peptides 2003; 24:1723-1731
37. Sambri V, Marangoni A, Giacani L, et al: Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema pallidum. J Antimicrob Chemother 2002; 50:895-902
38. Buck MA, Olah TA, Weitzmann CJ, et al: Protein estimation by the product of integrated peak area and flow rate. Anal Biochem 1989; 182:295-299
39. Edelhoch H: Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967; 6:1948-1954
40. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Fifth Edition. Approved Standard. M7-A5. Wayne, PA, National Committee for Clinical Laboratory Standards, 2001
41. Ginsburg I: The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS 2002; 110:753-770
42. Prins JM, Kuijper EJ, Mevissen MLCM, et al: Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: Influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63:2236-2242
43. Byl B, Clevenbergh P, Kentos A, et al: Ceftazidime- and imipenem-induced endotoxin release during treatment of Gram-negative infections. Eur J Clin Microbiol Infect Dis 2001; 20:804-7
44. van Langevel P, van Dissel JT, Ravensbergen E, et al: Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: Quantitative measurements and biological reactivities. Antimicrob Agents Chemother 1998; 42:3073-3078
45. Tomasz A, Waks S: Mechanism of action of penicillin: Triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis. Proc Natl Acad Sci U S A 1975; 72:4162-4166
46. Ruzin A, Singh G, Severin A, et al: Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:728-738